APA

Mösges R., Koch A. F., Raskopf E., Singh J., Shah-Hosseini K., Astvatsatourov A., Hauswald B., Yarin Y., Corazza F., Haazen L., Pirotton S., Allekotte S., Zadoyan G., Legon T., Durham S. R. & Shamji M. H. (20190807). Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients. : Allergy.

Chicago

Mösges R, Koch A F, Raskopf E, Singh J, Shah-Hosseini K, Astvatsatourov A, Hauswald B, Yarin Y, Corazza F, Haazen L, Pirotton S, Allekotte S, Zadoyan G, Legon T, Durham S R and Shamji M H. 20190807. Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients. : Allergy.

Harvard

Mösges R., Koch A. F., Raskopf E., Singh J., Shah-Hosseini K., Astvatsatourov A., Hauswald B., Yarin Y., Corazza F., Haazen L., Pirotton S., Allekotte S., Zadoyan G., Legon T., Durham S. R. and Shamji M. H. (20190807). Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients. : Allergy.

MLA

Mösges R, Koch A F, Raskopf E, Singh J, Shah-Hosseini K, Astvatsatourov A, Hauswald B, Yarin Y, Corazza F, Haazen L, Pirotton S, Allekotte S, Zadoyan G, Legon T, Durham S R and Shamji M H. Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients. : Allergy. 20190807.